The Lifespan Brief Editorial Desk
Senolytics Improved Liver Fibrosis in a Small Randomized Human Trial
A small randomized trial found improved liver fibrosis with dasatinib plus quercetin in people with MASH. The disease signal is encouraging, but…
FDA Officials Discuss How Longevity Drugs Could Be Evaluated
FDA officials at ARDD discussed possible evidence standards for longevity drugs. The conversation concerns regulatory science, not recognition of aging as a…
Transplanted Hearts May Take On the Biological Age of Their Recipient
A preprint links transplanted heart aging signatures to recipient age. Mouse experiments and human data suggest the surrounding body matters, with major…
Direct AMPK Activation Extended Lifespan in Yeast, Worms and Flies
Compound 991 extended lifespan in three model organisms by directly activating AMPK. Mouse protein changes suggest a research lead, not proof of…
Exercise Changed Aging Clocks in Cancer Survivors. Did It Actually Slow Aging?
A randomized 12-month exercise program improved sustained attention and changed two blood-based epigenetic aging measures in breast-cancer survivors. The clocks are promising…
Can Creatine Help Preserve Muscle Before Old Age? A New Trial Adds Evidence
A 12-week randomized creatine trial in adults aged 45 to 65 found modest gains in lean tissue and strength. The study is…
Longevica Wants to Turn a 16,000-Animal Longevity Screen Into New Drugs
Longevica says a $13 million screen tested 1,033 compounds in more than 16,000 mice. Its new advisory board may help build a…
Exceptional Longevity May Leave Clues in Health From the Start of Life
A Danish register study found lower infant mortality and fewer adverse birth outcomes among some descendants of exceptionally long-lived families, but the…
AI Can Read Aging Signals in the Chromatin of Blood Stem Cells
ChromAgeNet distinguished young from aged mouse blood stem cells by analyzing the three-dimensional organization of chromatin inside their nuclei. It is a…
Rejuvenation Technologies Gets New Backing for Telomere-Targeted mRNA Platform
Jetstream backed Rejuvenation Technologies’ targeted TERT mRNA platform. The programs remain preclinical, and funding is not clinical proof.